PLEASANTON, Calif.,
June 18 /PRNewswire-FirstCall/ --
Thoratec Corporation (Nasdaq: THOR), a world leader in device-based
mechanical circulatory support therapies to save, support and
restore failing hearts, said today that it will be participating in
the Wells Fargo Securities Healthcare Conference on Thursday, June 24.
Gary F. Burbach, president and
chief executive officer, will provide an update on the company,
beginning at 10:15 a.m., Eastern Daylight
Time (7:15 a.m., Pacific Daylight
Time).
The presentation will be available through the conference web
site at http://www.wsw.com/webcast/wa61/thor/, or on the company's
web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's product lines include
the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS
(Left Ventricular Assist System) with more than 15,000 devices
implanted in patients suffering from heart failure. Thoratec is
headquartered in Pleasanton,
California. For more information, visit the company's web
site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and IVAD is a
trademark of Thoratec Corporation. CentriMag is a registered
trademark of Levitronix, LLC.
SOURCE Thoratec Corporation